A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

NCT01572038 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1436

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Docetaxel
DRUG: Nab-paclitaxel
DRUG: Paclitaxel
DRUG: Pertuzumab
DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche